Plasma levels of soluble TNF receptors 1 and 2 after tDCS and sertraline treatment in major depression: Results from the SELECT-TDCS trial

Imagem de Miniatura
Arquivos
art_BRUNONI_Plasma_levels_of_soluble_TNF_receptors_1_and_2015.PDF (330.25 KB)
Citações na Scopus
18
Tipo de produção
article
Data de publicação
2015
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
MACHADO-VIEIRA, Rodrigo
VIEIRA, Erica L. M.
CARVALHO, Andre F.
CHO, Hyong Jin
GATTAZ, Wagner F.
Citação
JOURNAL OF AFFECTIVE DISORDERS, v.185, p.209-213, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: The cytokine hypothesis of depression postulates that the pathophysiology of this illness incorporates an increased production of pro-inflammatory cytokines, which leads to an over activation of the hypothalamic-pituitary-adrenal axis as well as monoaminergic disturbances. Nevertheless, it remains unclear whether the amelioration of depressive symptoms could decrease cytokine levels. Notwithstanding antidepressant drug therapy might exert anti-inflammatory effects, the effects of non-invasive neuromodulatory approaches like transcranial direct current stimulation (tDCS) on pro-inflammatory cytokine networks are largely unknown. Methods: We evaluated, in the Set-Leanne vs. Eleciric Curreni Therapy for TreaLing Depression Clinical SLudy (SELECT-TDCS) fetal, whether the plasma levels of the soluble TNF recepLors 1 and 2 (sTNFRs) changed tiller anLiclepressanL LreaLmeni in a sample of 73 anLidepressanL-free paLienis with unipolar depressive disorder in an episode of aL leasL mocleraLe inLensiLy. Results: Although boat LDCS and set-Leanne exerLed anLiclepressanL effecfs. the plasma levels of sTNFRs did noi change over Lime regardless of Lhe infervenLion and clinical response. Also, baseline sTNFRs levels did noL predicL anLiclepressanL response. Limitations: Our negative findings could be a type LI error, as this trial did not use an equivalence design. Conclusions: To conclude, in this novel placebo-controlled trial prospectively evaluating the changes of sTNFRs in depressed patients, we found that these molecules are not surrogate biomarkers of treatment I esponse of tDCS, whose antidepressant effects occurred regardless of normalization of immunological activity.
Palavras-chave
Major depressive disorder, Transcranial direct current sdmulation, Sertraline, STNFR1, STNFR2
URI
https://observatorio.fm.usp.br/handle/OPI/11549
Referências
  1. Brunoni A. R., 2013, INT J NEUROPSYCHOPHA
  2. Brunoni AR, 2013, JAMA PSYCHIAT, V70, P383, DOI 10.1001/2013.jamapsychiatry.32
  3. Brunoni AR, 2011, CONTEMP CLIN TRIALS, V32, P90, DOI 10.1016/j.cct.2010.09.007
  4. Brunoni AR, 2014, PSYCHOPHARMACOLOGY, V231, P1315, DOI 10.1007/s00213-013-3322-3
  5. Brunoni AR, 2014, EUR NEUROPSYCHOPHARM, V24, P1144, DOI 10.1016/j.euroneuro.2014.03.006
  6. Brunoni AR, 2014, PROG NEUROPSYCHOPH C, V56C, P91
  7. Dean B, 2013, MOL PSYCHIATR, V18, P767, DOI 10.1038/mp.2012.95
  8. DellaGioia N, 2010, NEUROSCI BIOBEHAV R, V34, P130, DOI 10.1016/j.neubiorev.2009.07.014
  9. Fornaro M, 2013, J AFFECT DISORDERS, V145, P300, DOI 10.1016/j.jad.2012.08.007
  10. Grassi-Oliveira R, 2009, PSYCHIAT CLIN NEUROS, V63, P202, DOI 10.1111/j.1440-1819.2008.01918.x
  11. Hannestad J, 2011, NEUROPSYCHOPHARMACOL, V36, P2452, DOI 10.1038/npp.2011.132
  12. Howren MB, 2009, PSYCHOSOM MED, V71, P171, DOI 10.1097/PSY.0b013e3181907c1b
  13. Kohler O, 2014, JAMA PSYCHIAT, V71, P1381, DOI 10.1001/jamapsychiatry.2014.1611
  14. Lanquillon S, 2000, NEUROPSYCHOPHARMACOL, V22, P370, DOI 10.1016/S0893-133X(99)00134-7
  15. Maes M, 2011, PROG NEURO-PSYCHOPH, V35, P769, DOI 10.1016/j.pnpbp.2010.06.008
  16. Mueller N, 2007, MOL PSYCHIATR, V12, P988, DOI 10.1038/sj.mp.4002006
  17. Munzer A, 2013, TOXINS, V5, P2227, DOI 10.3390/toxins5112227
  18. Raison CL, 2013, JAMA PSYCHIAT, V70, P31, DOI 10.1001/2013.jamapsychiatry.4
  19. Teixeira AL, 2015, HUM PSYCHOPHARM CLIN, V30, P52, DOI 10.1002/hup.2450
  20. Valkanova V, 2013, J AFFECT DISORDERS, V150, P736, DOI 10.1016/j.jad.2013.06.004
  21. Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189
  22. Xia ZL, 1996, IMMUNOPHARMACOLOGY, V34, P27, DOI 10.1016/0162-3109(96)00111-7
  23. Young JJ, 2014, J AFFECT DISORDERS, V169, P15, DOI 10.1016/j.jad.2014.07.032

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/20
Artigos e Materiais de Revistas Científicas - LIM/27
Artigos e Materiais de Revistas Científicas - ODS/03